多发性骨髓瘤的核医学显像,尤其关注复发场景
多发性骨髓瘤患者中溶骨性病变发生率高达90%,全身X线在复发时因治疗后病灶持续存在而难以区分新旧病灶。本文综述靶向代谢、表面受体和血管生成的放射性药物在复发多发性骨髓瘤分期和疗效监测中的效果,并提及部分示踪剂可能用于放射免疫治疗。
要点
- 全身X线因治疗后病灶持续存在,在复发多发性骨髓瘤中区分新旧病灶的能力有限。
- 靶向代谢、表面受体和血管生成的放射性药物可用于复发多发性骨髓瘤的分期和疗效监测。
- 部分示踪剂可能用于放射免疫治疗。
核心结论
- 现有文献数据、新示踪剂的初步结果和我们的试点工作表明,多种放射性药物应用可有效用于复发多发性骨髓瘤患者的分期和疗效监测。
- 部分示踪剂可能用于放射免疫治疗。
研究设计与样本
- 综述,总结靶向代谢、表面受体和血管生成的放射性药物的文献数据及作者试点工作。
主要发现
- 多发性骨髓瘤以骨髓单克隆浆细胞群为特征,溶骨性病变发生率高达90%。
- 全身X线因治疗后病灶持续存在,限制其区分陈旧非活动性骨病灶与新活动性病灶的能力。
- 磁共振成像、正电子发射断层扫描和计算机断层扫描等现代影像技术对骨髓瘤骨病和髓外表现的检测优于全身X线。
- 核医学显像通过直接靶向恶性浆细胞的特异性细胞特性,能够识别疾病活动性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is characterized by a monoclonal plasma cell population in the bone marrow. Lytic lesions occur in up to 90 % of patients. For many years, whole-body X-ray (WBX) was the method of choice for detecting skeleton abnormalities. However, the value of WBX in relapsing disease is limited because lesions persist post-treatment, which restricts the capacity to distinguish between old, inactive skeletal lesions and new, active ones. Therefore, alternative techniques are necessary to visualize disease activity. Modern imaging techniques such as magnetic resonance imaging, positron emission tomography and computed tomography offer superior detection of myeloma bone disease and extramedullary manifestations. In particular, the properties of nuclear imaging enable the identification of disease activity by directly targeting the specific cellular properties of malignant plasma cells. In this review, an overview is provided of the effectiveness of radiopharmaceuticals that target metabolism, surface receptors and angiogenesis. The available literature data for commonly used nuclear imaging tracers, the promising first results of new tracers, and our pilot work indicate that a number of these radiopharmaceutical applications can be used effectively for staging and response monitoring of relapsing MM patients. Moreover, some tracers can potentially be used for radio immunotherapy.
引用
- de Waal EGM, Glaudemans AWJM, Schröder CP, et al. Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting. Eur J Nucl Med Mol Imaging. 2016. PMID: 27900520. doi:10.1007/s00259-016-3576-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。